Pfizer Planning To Start Phase III DMD Gene Therapy Trial, With Safety Monitoring Protocols

 
• By Jessica Merrill

Updated Phase Ib data showed safety issues due to complement activation, but Pfizer is confident the benefits outweigh the risks and monitoring systems will help as it moves into Phase III.

Caution sign
Positive efficacy signals but safety risks too with Pfizer's DMD gene therapy • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies